Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Publications from the Centre for Immuno-Oncology

High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma

Hill SL. et al, (2024), Cancer Immunology, Immunotherapy, 73

Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.

Brackenridge S. et al, (2024), J Virol

CD137 (4-1BB) and T-Lymphocyte Exhaustion.

Molero-Glez P. et al, (2024), Clin Cancer Res, OF1 - OF3

Integrating Patient and Public Involvement and Engagement in Translational Medicine

Borrow P. et al, (2024), The Lancet

A high affinity monoclonal antibody against HLA-E-VL9 enhances natural killer cell anti-tumor killing

Hwang JK. et al, (2024)

Cross-talk between ILC2 and Gata3high Tregs locally constrains adaptive type 2 immunity.

Stockis J. et al, (2024), Science immunology, 9

Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3.

Sim MJW. et al, (2024), European journal of immunology

Update: Vitamin D3 and calcium carbonate supplementation for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology (VITALITY trial): study protocol for a randomised placebo-controlled trial.

Dzavakwa NV. et al, (2024), Trials, 25

Closing the equity gap in the treatment of HIV-2 infection.

Rowland-Jones S. and Gea-Mallorquí E., (2024), The lancet. HIV, 11, e347 - e349

Double-stranded RNA to mimic viral infection for cancer immunotherapy.

Martinez-Riaño A. et al, (2024), Clinical cancer research : an official journal of the American Association for Cancer Research

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Melero I. et al, (2024), Annals of oncology : official journal of the European Society for Medical Oncology, 35, 537 - 548

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.

Segal NH. et al, (2024), Nature communications, 15

Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities.

Lopez Janeiro A. et al, (2024), Journal for immunotherapy of cancer, 12

Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Load More

1
2
3
4
5
6
7
...
»